Stifel lowered the firm’s price target on NervGen Pharma (NGEN) to $5.50 from $6.75 and keeps a Buy rating on the shares after having hosted an update with NervGen’s CEO and largest shareholder, Adam Rogers. The firm sees NervGen’s clean capital structure and near-term de-risking catalysts supporting capital requirements and overall, leading to a greater share price, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
- NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
- NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
- NervGen Pharma to delist shares from TSX
- NervGen Pharma price target raised to C$6.75 from C$5 at Stifel